| Authors: |
Awan FT; UT Southwestern Medical Center, Dallas, Texas, USA Farrukh.Awan@UTSouthwestern.edu., Gamse JT; Genmab US Inc, Plainsboro, New Jersey, USA., Overdijk MB; Genmab BV, Utrecht, The Netherlands., Breij ECW; Genmab BV, Utrecht, The Netherlands., Jure-Kunkel M; Genmab US Inc, Plainsboro, New Jersey, USA., Sanghavi K; Genmab US Inc, Plainsboro, New Jersey, USA., Brady LK; Genmab US Inc, Plainsboro, New Jersey, USA., Guan M; Genmab US Inc, Plainsboro, New Jersey, USA., Verbrugge I; Genmab BV, Utrecht, The Netherlands., Chen J; Genmab US Inc, Plainsboro, New Jersey, USA., Gong N; Genmab US Inc, Plainsboro, New Jersey, USA., Gillespie M; Genmab US Inc, Plainsboro, New Jersey, USA., Tees M; Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, Colorado, USA., Gallogly M; Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio, USA., Hutchings M; Rigshospitalet, Copenhagen, Denmark.; University of Copenhagen, Copenhagen, Denmark., Christensen JH; Odense University Hospital, Odense, Denmark., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet, IDIBELL, Barcelona, Spain.; Universitat de Barcelona, Barcelona, Spain., Cordoba R; Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain., Ahmed S; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Woei-A-Jin FJSH; University Hospitals Leuven, Leuven, Belgium., Abrisqueta P; Hospital Universitario Vall d'Hebron, Barcelona, Spain., Giné E; Hospital Clínic IDIBAPS, Barcelona, Spain., Roost Clausen M; Vejle Hospital, Vejle, Denmark., Bhat SA; Division of Hematology, The Ohio State University, Columbus, Ohio, USA., Gopal AK; Fred Hutchinson Cancer Center at UW Medical Center - Northwest, Seattle, Washington, USA., Chamuleau MED; On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. |
